Narrow Results

Phylogica to Discover Peptide-based Vaccines with Pfizer.

TGR BioSciences Partners with Cedarlane.

China Sky One Medical Cultivates TCM Herbs in Northeast China.

Chindex and Fosun Pharma Ink Joint Venture.

China SHESAYS Introduces Sirona's CEREC AC Dental Restoration Robot.

Novozymes Opens New R&D Center in India.

Avila, Sanofi-aventis Partner to Develop Targeted Covalent Oncology Drugs.

Biogen Idec Launches Tysabri for Multiple Sclerosis Treatment in India.

GSK, Impax in $11.5 mn Deal for Parkinson's Drug.

Eisai Enters Local Oncology Market with Treakisym.

RaQualia Announces Collaboration and License Agreement With Lilly for Pain Treatments.

Bristol-Myers Squibb and Oncolys BioPharma Enter Global Licensing Agreement for Investigational HIV Compound.

A*STAR and Cytos Extend Influenza Vaccine Collaboration to Supply of Clinical Trial Material.

Cellular Biomedicine Group (CBMG) and GE Healthcare Life Sciences China Announce Strategic Partnership to Establish Joint Technology Laboratory to Develop Control Processes for the Manufacture of CAR-T and Stem Cell Therapies.

Zuellig Pharma to Invest over $50 Million in Singapore-Based Innovation Centre.

Holmusk: Using Data to Improve Clinical Outcomes for Cardiovascular Disease in Singapore.

Singapore Eye Bank Sets Another Record in Local Cornea Donations in 2016.

Plasticell and King’s College London to Collaborate in Trials of Blood Platelet Substitute.

Merck Partners with University of California, San Diego (UCSD) to Fight Neglected Tropical Diseases.

Mundipharma Wins Approval for Antineoplastic Agent mundesine® as Treatment for Relapsed/Refractory Peripheral T-cell Lymphoma in Japan.

Asian Myeloma Network (AMN) Brings Clinical Trials to Cancer Patients in Asia and Provides Early Access to Effective Drugs.

APBN Interview with Professor Chng Wee Joo.

The epidemiology of lymphoma varied greatly among different ethnic groups in the world. The incidence and spectrum of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) in Asian countries is different from that in Western countries and varies within Asia itself. An increasing incidence in lymphoma reported from Caucasian data is also seen in Asia, albeit at a lower rate. Key features of lymphoma epidemiology in Oriental countries include a lower incidence of HL, follicular lymphoma and in particular chronic lymphocytic leukemia, but a higher incidence of extranodal lymphoma and T and NK lineage disease. This may be related to differences in social economic conditions, genetic susceptibility and infective agents. Treatment results in Asian lymphoma cases do not seem to differ from Western counterparts. The epidemiology pattern is, however, likely to change with improved living conditions, longer life expectancy, Westernized living habits and the HIV epidemic.

Neoplasms of natural killer (NK) cells are a group of uncommon but highly aggressive malignancies with a strong geographic predilection, and predominantly involving extranodal sites, particularly the nasal/nasopharyngeal region, and sometimes extranasal areas such as the skin and gastrointestinal tract. This group of tumors is characterized: 1) pathologically by an angiocentric and angiodestructive infiltrate of lymphoid cells that can span a broad cytologic spectrum, and that frequently contain cytologic granules; 2) phenotypically by the expression of CD2, cytoplasmic CD3_ε and CD56, but not surface CD3 or T cell receptor (TCR); 3) genotypically by a germline configuration of TCR genes; and 4) by a very strong association with Epstein-Barr virus (EBV). According to the clinicopathologic features, they are classified by the World Health Organization (WHO) into: 1) extranodal NK/T cell lymphoma; and 2) aggressive NK cell leukemia. The entity currently known as blastic NK cell lymphoma is probably not a genuine NK cell neoplasm. NK cell neoplasms are one of the most aggressive hematolymphoid malignancies, and are often resistant to conventional combination chemotherapy.

Doxorubicin (DOX) plays an important part in lymphoma treatment. However, various side effects on normal tissues restrict its clinical use. Nanocarriers connected by Gly–Phe–Leu–Gly (GFLG) can be equipped with the advantages of nanoparticles (NPs), their enhanced permeability and retention (EPR) effect, and surface modifiability. Nanocarriers can also be specifically enzymatically hydrolyzed by cathepsin (Cath) B, a kind of enzyme highly expressed in tumor cells. In this work, we proposed a novel drug delivery system comprising GFLG conjugated with copper sulfide (CuS) NPs loaded with DOX. The system, designated as CuS-GFLG-DOX, could be used for NP-based targeted combination chemotherapy. Results showed that the drug delivery system had an appropriate diameter, good dispersibility, high encapsulation efficiency and high drug loading. The system also exhibited an excellent targeting of lymphoma cells and an enhanced antitumor activity. The possible pathway to induce cytotoxic effects was Bcl-2/caspase-mediated apoptosis pathway. In conclusion, CuS-GFLG-DOX could precisely deliver drugs to lymphoma cells and could be a novel and promising therapeutic option for lymphoma.